直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
A. Sasha Hoyt
Associate
More
vCard
  • 901 New York Avenue, NW
  • Washington, DC 20001-4413
+1 202 408 4230
sasha.hoyt@finnegan.com sasha.hoyt@finnegan.com

A. Sasha Hoyt

Associate

  • +1 202 408 4230 +1 202 408 4230
  • sasha.hoyt@finnegan.com sasha.hoyt@finnegan.com
  • 901 New York Avenue, NW
  • Washington, DC 20001-4413
  • vCard

Sasha Hoyt focuses on complex patent and trade secret litigation, as well as post-grant proceedings, client counseling, and opinion work related to chemicals, pharmaceuticals, and manufacturing. She represents clients before U.S. district courts, with a particular emphasis on litigating Abbreviated New Drug Application (ANDA) cases involving polymorph and drug-drug interaction patents. Sasha also provides strategic litigation counseling and monitoring, as well as guidance to clients on infringement, validity and enforceability issues.  

Sasha has extensive experience representing innovators in litigations involving treatments for complex medical conditions against multiple defendants, both corporations and individuals. She is actively involved in all phases of litigation, from pre-litigation counseling and strategy development, to managing comprehensive fact and expert discovery on accelerated timelines, as well as claim construction, trial preparation, and settlement.  Sasha's work has contributed to favorable outcomes for clients, including successful settlements. 

 

While in law school, Sasha served as a judicial extern to the Honorable Michael F. Urbanski, Chief District Judge of the U.S. District Court for the Western District of Virginia. She also worked at the University of Virginia’s Licensing and Ventures Group during and prior to law school.

 

Sasha is committed to pro bono service and has been recognized multiple times on the Capital Pro Bono Honor Roll and High Honor Roll for her representation of asylum seekers, including securing a grant of asylum for a client in a complex proceeding involving multiple hearings and experts in foreign law.  She has also volunteered with the Election Protection Hotline.

 

Et Cetera

  • Author. “The Impact of Uncertainty Regarding Patent Eligible Subject Matter for Investment in U.S. Medical Diagnostic Technologies,” Washington and Lee Law Review, Winter, 2022.
  • Coauthor. “NPEs and Evolving Standards for Licensing-Based Domestic Industries at the ITC,” Paul J Luckern Summer Associate Edition of the ITC Trial Lawyers Association 337 Reporter, Feb. 2022.
  • Presenter. “The Impact of Uncertainty Regarding Patent Eligible Subject Matter for Investment in U.S. Medical Diagnostic Technologies,” Student Notes Colloquium, Sept. 2021.
  • Executive Editor, Washington and Lee Law Review, 2021–2022.

Experience

Rocket Pharmaceuticals, Inc. v. Beard et al.

Represented Rocket Pharmaceuticals, Inc. in district court litigation involving claims of trade secret misappropriation and breach of contract against corporate and individual defendants relating to complex treatments for genetic disorders. Obtained successful outcome including permanent injunction and other remedies against all defendants.

3:24-cv-02170, D. Or., Judge Simon

Rocket Pharmaceuticals, Inc. v. Lexeo Therapeutics, Inc., et al.

Represented Rocket Pharmaceuticals, Inc. in district court litigation involving claims of trade secret misappropriation and breach of contract against individual and corporate defendants and relating to complex treatments for genetic disorders. Successfully opposed motion to dismiss key claims and obtained settlement with all defendants following completion of fact discovery.

1:23-cv-09000, S.D.N.Y., Judges Castel, Aaron

Insights

At the PTAB Blog

IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026 IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026

May 26, 2026

At the PTAB Blog

IPR and PGR Statistics for Final Written Decisions Issued in November 2025 to January 2026 IPR and PGR Statistics for Final Written Decisions Issued in November 2025 to January 2026

March 6, 2026

At the PTAB Blog

IPR and PGR Statistics for Final Written Decisions Issued in September and October 2025 IPR and PGR Statistics for Final Written Decisions Issued in September and October 2025

December 19, 2025

At the PTAB Blog

IPR and PGR Statistics for Final Written Decisions Issued in June 2025 IPR and PGR Statistics for Final Written Decisions Issued in June 2025

July 24, 2025

At the PTAB Blog

PTAB Statistics for Final Written Decisions Issued in March and April 2025 PTAB Statistics for Final Written Decisions Issued in March and April 2025

June 4, 2025

At the PTAB Blog

PTAB Statistics for Final Written Decisions Issued in December 2024 and January 2025 PTAB Statistics for Final Written Decisions Issued in December 2024 and January 2025

February 28, 2025

More

News

Award/Ranking

61 Finnegan Attorneys Recognized on the 2025 Capital Pro Bono Honor Roll 61 Finnegan Attorneys Recognized on the 2025 Capital Pro Bono Honor Roll

May 7, 2026

Award/Ranking

56 Finnegan Attorneys Recognized on the 2024 Capital Pro Bono Honor Roll 56 Finnegan Attorneys Recognized on the 2024 Capital Pro Bono Honor Roll

April 24, 2025

DC Bar

Award/Ranking

60 Finnegan Attorneys Named to 2023 Capital Pro Bono Honor Roll

60 Finnegan Attorneys Named to 2023 Capital Pro Bono Honor Roll

May 15, 2024

Professional Activities

  • Order of the Coif
Admissions and Education

Admissions

  • U.S. Patent and Trademark Office
  • District of Columbia

Education

Washington and Lee University School of Law
J.D., summa cum laude, 2022
University of Virginia
B.A., Chemistry and Cognitive Science, with high distinction, 2018

Languages

  • French

A.'s Practices

AI + Finnegan
AI + Patent
Global IP Enforcement, Litigation, and Trials
Branded Hatch-Waxman (ANDA) Litigation and Trials
Prosecution and Portfolio Management
Licensing, Pooling, and Other Transactions
Opinions and Counseling
Patent Drafting and Prosecution

A.'s Industries

AI, Electronics, and Information Technology
Artificial Intelligence (AI) and Machine Learning (ML)
Augmented Reality/Virtual Reality (AR/VR)
Chemicals, Industrials, and Materials
Chemical
Manufacturing
Communications
Financial Services and Business Systems
Hospitality, Gaming, and Leisure
Gaming
Sports, Fitness, and Outdoor Recreation
Life Sciences
Medical Device and Diagnostics
Pharmaceutical

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP